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ABSTRACT 
IDENTIFYING AGGREGATIBACTER ACTINOMYCETEMCOMITANS 
PERIODONTAL ANTIGENS BY IMMUNOSCREENING 
Gerald B. Pevow 
May 4, 2012 
Periodontitis is a chronic, destructive inflammatory disease of the supporting 
tissues of the teeth with a high prevalence among adults. While the complete 
pathogenesis of periodontitis remains unclear, it is initiated and sustained by dental 
plaque containing pathogens such as Porphyromonas gingivalis, Aggregatibacter 
actinomycetemcomitans, Bacteroides forsythus, and Prevotella intermedia. 
Our hypothesis is that multiple antigens are recognized by human antibodies, and 
antigens can be identified by use of a genomic expression library. We developed an 
unbiased global approach to define A. actinomycetemcomitans protein antigens that elicit 
humoral immune responses and developed a screening method to identify periodontal 
antigens. We identified 19 unique antigens, 17 of which have not been studied in A. 
actinomycetemcomitans 
Future studies should 1) use additional human sera to identify additional antigens, 
2) elucidate the role of identified antigens, and 3) determine how A. 
actinomycetemcomitans antigen-antibody profiles relate to disease progression. 
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INTRODUCTION 
Periodontitis is a chronic, destructive, multifactorial inflammatory disease of the 
supporting tissues of the teeth with a high prevalence among the adult population. 
Whereas the complete pathogenesis and mechanism of periodontal disease progression 
remains unclear, it is initiated and sustained by dental plaque containing bacterial 
pathogens. Some of the most commonly investigated periodontal pathogens include 
Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Bacteroides 
forsythus, and Prevotella intermedia (Lovegrove, 2004). 
Plaque-induced periodontal diseases are mixed infections associated with 
relatively specific groups of oral bacteria (Armitage, 2009, Lovegrove, 2004, Socransky, 
2002). Patient susceptibility and disease progression is highly variable, depending on 
both environmental factors and the host responses to periodontal pathogens (Zambon, 
1996; Komman, 1997; Van Dyke, 2005; Darveau, 2009). Risk factors for periodontal 
disease include but are not limited to smoking, age, diabetes mellitus, stress (depression, 
anxiety, job or financial strain), gender, medication, socio-economic status and HIV 
infection (Ng, 2006; Armitage, 2003, Corbet 2011). 
To arrive at a periodontal diagnosis, clinicians observe the presence or absence of 
signs of inflammation such as 1) bleeding on probing; 2) probing depths; 3) extent and 
pattern of loss of clinical attachment and bone; 4) patient's medical and dental histories; 
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and 5) presence or absence of additional clinical indicators such as pain, ulceration, and 
the amount of plaque and calculus. Inflammation without observable connective tissue 
attachment loss is termed gingivitis while inflammation with attachment loss is termed 
periodontitis (Armitage, 2010). 
Periodontitis is a common dental disorder. However, estimates of the exact 
prevalence of periodontitis in the U.S. and worldwide vary due to inconsistent disease 
definition and study methodology (Costa, 2009). If periodontitis is defined as the 
identification of at least one site with Clinical Attachment Loss I (CAL) of 2': 2 mm, 
around 80% of all adults are affected, and around 90% of those aged 55 to 64 (Centers for 
Disease Control, 1997). However, if the case definition is at least one site with CAL of 2': 
4 mm, the prevalence in those aged 55 to 64 drops to around 50%, and with a case 
definition of CAL 2': 6 mm, prevalence is less than 20% (Burt, 2005; Baelum, 2003). 
Despite efforts by the Center for Disease Control and Prevention and the American 
Academy of Periodontology to develop consensus, the discussion of definitions of 
periodontal diseases and periodontitis continues (Corbet, 2011; Meisel, 2009). 
Nevertheless, by any definition, a large portion of the U.S. population suffers from 
periodontitis. 
Periodontitis is caused by inflammation and infection of the tissues that support 
the teeth and is characterized by the loss of attachment between the teeth and the 
surrounding tissues. It is classified as chronic or aggressive periodontitis based on the 
differing rates of loss of attachment of the teeth and the patient's age and medical status 
(Armitage, 1999; Armitage, 2010; Schaudinn, 2009). Chronic periodontitis, the most 
I Clinical attachment loss (CAL) is the predominant clinical manifestation and determinant of periodontitis. 
It is calculated as the clinician's probing depth measurement plus hislher gingival margin level 
measurement. 
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common type of periodontitis, is typically a slowly progressing disease that emerges 
clinically in adulthood and continues throughout life. By contrast, aggressive 
periodontitis is less common than chronic periodontitis and principally affects young 
people (Armitage, 2003; Armitage, 2010). 
Further, chronic and aggressive periodontitis is characterized by extent (localized 
or generalized) and severity (slight, moderate, and severe). By definition, localized 
periodontitis affects less than 30% of sites while generalized periodontitis affects 30% or 
more sites (Savage, 2009). Also by definition, severity is measured by clinical attachment 
loss (CAL) as follows: Slight = 1-2mm, Moderate = 3-4 mm, and Severe ~ 5 mm 
(Armitage, 2003; Armitage, 2010). 
The disorder is initiated by dental plaque, a microbial biofilm. Like other biofilm 
infections, periodontitis is refractory to antibiotic agents and host defenses because the 
causative microbes live in complex communities that persist despite challenges. Oral 
health or disease depends on the interface between the host and the microbial community 
as a whole. Further, both the pathogenicity of specific microbes and the community 
within which they reside are important to study (Jenkinson, 2005; Kuramitsu, 2007; 
Schaudinn, 2009). 
Bacteria play an essential role in the etiology of periodontal disease. Over 700 
bacterial species have been identified in the oral cavity and nearly 300 species have been 
cultured and found to contribute to the biofilm of the periodontal pocket (Dewhirst, 2010; 
Jenkinson, 2005; Loesche, 2001; Nibali, 2009; Paster, 2001; Picolos, 2005). However, 
the direct involvement of each individual microbe in pathogenesis remains unclear. Some 
of the most commonly investigated periodontal pathogens include Porphyromonas 
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gingivalis, Aggregatibacter actinomycetemcomitans, Bacteroides forsyth us, and 
Prevotella intermedia based on earlier work associating bacterial species with severity of 
disease (Haffajee, 1994). 
Aggregatibacter actinomyctemcomitans, formerly Actinobacillus 
actinomycetemcomitans, is a gram-negative, facultative anaerobic coccobacillus 
bacterium that colonizes the oral cavities of humans (Norskov-Lauitsen, 2006; Henderson 
2011). Several studies have shown that A. actinomycetemcomitans is significantly 
associated with both aggressive periodontitis and chronic periodontitis (Ebersole, 1995a; 
Zambon, 1996; Loesche, 2001; Cortelli, 2005; Rylev, 2008). The association is clearly 
greatest with aggressive periodontitis. However, strong associations have been reported 
for A. actinomycetemcomitans with chronic periodontitis patients, 74% (Choi, 2000); 
50% (Kuboniwa, 2004); >75% (Rodrigues, 2004); 30% (Slots, 1990); 60% (Sixou, 
1991); 75% (Savitt, 1991); 28% (Sandholm, 1987); 55% (Flemmig, 1996). 
Additional evidence linking A. actinomycetemcomitans with periodontitis is that 
there is a clear immune response of the host to A. actinomycetemcomitans infection 
(Kinane, 1999; Apatzidou, 2004). Further, certain anti-A. actinomycetemcomitans serum 
antibodies appear to protect patients from disease (Flemmig, 1996; Lamster, 1998). Such 
data have led reviewers to generally conclude that A. actinomycetemcomitans is likely a 
periodontal pathogen in humans (Zambon, 1996; Kinane, 2000b; Kinane, 2001a; 
Loesche, 2001; Henderson, 2002; Mombelli, 2002; Henderson, 2003; Lovegrove, 2004). 
This conclusion is supported by experimental evidence in animal models including 
miniature pigs, dogs, rats, and mice which demonstrates that A. actinomycetemcomitans 
does cause periodontal disease (Freire, 2011; Fine, 2009; Oz, 2011). 
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The onset and severity of periodontal disease is largely controlled by the 
effectiveness of the immune response of the patient to the oral pathogens. As contributors 
to the immune response, several lines of evidence indicate that peripheral serum 
antibodies are relevant to disease progression: Immunization against A. 
actinomycetemcomitans bacteria can attenuate infection-induced periodontitis-like 
disease, and total serum antibody levels correlate with decreased severity of disease 
(Casarin, 2010; Rams, 2006). 
However, high serum antibody titers do not always prevent disease. Thus, 
analysis of specific host antibodies to specific bacterial antigens is likely to be more 
informative than gross analysis of total serum immunoglobulin levels. This is the premise 
of the present work and from which we developed the project hypothesis: Antibodies to 
certain A. actinomycetemcomitans bacterial proteins are very highly associated with the 
severity of, and response to, treatment of periodontal disease. 
Several such studies of specific host antibodies have investigated one or very few 
antibody/antigen relationships at a time. These studies indicate the clinical significance of 
serum antibodies. However, it remains unclear whether some groups of antibodies elicit 
better protection than others. 
The purpose of this study was to identify immunoreactive A. 
actinomycetemcomitans proteins by use of an unbiased genomic DNA lambda phage 
expression library. The method allows for a global screening approach to identify all 
protein epitopes encoded on the bacterial genome that may elicit a human antibody 
response. Bacterial protein antigens that elicit a humoral response can then be further 
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studied and associations drawn between the immune response and clinical indices. The 
four main goals of this research project are to: 
1. create bacteriophage lambda genomic expression libraries expressing peptides 
encoded on the A. actinomycetemcomitans genome, 
2. develop the immunoscreening method as a broad approach to find novel bacterial 
antigens, 
3. optimize the immunoscreening method for this project and immunoscreen whole 
celllysates from A. actinomycetemcomitans JP2, and 
4. identify and characterize A. actinomycetemcomitans antigens obtained through the 
optimized immunoscreening method. 
While the research used an unbiased global approach to define novel bacterial 
protein antigens that elicit humoral immune responses, there are other methods to identify 
novel protein antigens, most notably IVIAT, In Vivo Induced Antigen Technology 
(Handfield, 2000; Cao 2004). IVIAT also uses bacterial genomic DNA expression 
libraries, supporting the utility of such an approach. However, the goal of the IVIA T 
approach is the opposite of the goal of this research. IVIA T seeks to identify the 
bacteria's response to living inside the host, whereas we seek to identify a major 
component of the host's response to the bacteria. Further, the IVIA T technology requires 
pooled sera and is not easily compatible with creation of microarrays. 
A future goal for this project is to identify a discrete set of the most informative 
antigen proteins for use as prognostic diagnostic indicators. Such indicators may be of 
interest to determine whether the antibody profile of patients with gingivitis will develop 
6 
periodontitis in the future. This is based on the idea that certain antigen-specific 
antibodies confer protection from disease whereas other antigen-specific antibodies do 
this poorly. A micro array would be a simple approach to identify whether a given patient 
has serum antibodies that correlate with a protective response. Arranged in a micro array, 
the antigens have the potential for broad use as a prognostic diagnostic tool in the setting 
of a clinical lab. 
Further, such antigenic proteins may be useful as a vaccine to confer resistance 
against periodontal disease. If certain A. actinomycetemcomitans antigenic proteins cause 
an immune response in humans that protects against periodontitis, those proteins could 
then be used as a vaccine candidate to prevent disease. 
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METHODS AND MATERIALS 
Bacteriophage Lambda Genomic DNA Expression Libraries 
The goal of this research is to identify bacterial proteins which are antigenic in 
patients. This is done by using human sera to screen an unbiased bacterial genomic DNA 
expression library. Libraries are collections of cloned DNA fragments. Ideally, they 
contain a complete representation of genomic or cDNA sequences. They are commonly 
"packaged" in bacteriophage vectors. Different library types have different utilities and 
starting material. The most common types are cDNA libraries or genomic libraries. 
cDNA libraries contain only complementary DNA molecules synthesized from 
mRNA in a cell. Because cDNA libraries are copied directly from mRNA molecules they 
will only contain DNA representing mature mRNAs, i.e. intron sequences are not present. 
cDNA libraries have been essential for isolation of novel mRNAs. However, they 
typically over-represent abundant RNAs and may lack rare mRNAs. Also, cDNA 
libraries lack information about enhancers, introns, and other regulatory elements found 
in a genomic DNA library. 
Genomic libraries contain random DNA fragments representing the entire genome 
of an organism. Genomic libraries are useless for expression of eukaryotic genes since 
these genes contain introns. However, bacterial genes lack introns. Use of bacterial 
genomic DNA for an expression library provides a better representation of bacterial 
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peptides than a bacterial cDNA library constructed from mRNAs since different mRNAs 
are likely expressed during in vitro culture than in vivo. Hence, this approach is not 
biased by the initial abundance of mRNAs. This research project takes advantage of the 
extremely high gene density of the bacterial genome, which lacks introns, and the project 
uses genomic libraries since bacterial genes expressed selectively in the oral cavity may 
be severely under-represented in a cDNA library. 
The first step in genomic library preparation is the isolation of large fragments of 
chromosomal DNA (Figure 1). Extraction conditions should break open the cells to 
release the DNA but should minimize the shearing of DNA into small pieces. Also 
endogenous nuclease activity should be minimized in order to keep the DNA intact. 
Once large fragments of DNA are isolated, they need to be cut into the right size 
to be inserted into a vector. Not onlydo the fragments need to be sized correctly, but they 
also need to cut the DNA randomly so that the library will contain a collection of 
overlapping fragments. Such a collection ensures that all regions of the chromosome are 
equally represented. The best way to accomplish this is to partially digest the DNA with 
restriction endonucleases. Restriction digests not only cut DNA into the appropriate sizes, 
but also generate fragments with sticky ends that allow for easy insertion into the vector 
of choice. A restriction digest will leave some DNA fragments that are too large and 
some that are too small to use in a library. Thus, upon completion of a restriction digest, 
the appropriate sized fragments are fractionated by gel electrophoresis, cut from the gel 
and then purified to isolate the fragments from the gel. Once the fragments of DNA are 
isolated, they need to be inserted into a vector to generate the genomic library. The most 
commonly used vectors for genomic libraries are lambda derivatives that have large 
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Figure 1. Genomic DNA Library Construction 
Target DNA 
Digest w ith 
Restriction Enzyme 
~ 
DNA Fragments 
~NA recombination, 
, ~~ckaging, assembly 
Phage 
! ! 
Infect E. coli 
Figure 1. Genomic DNA Library Construction. Target DNA is partially digested with a 
restriction endonuclease resulting in overlapping DNA fragments of varying lengths. 
DNA fragments are packaged and assembled in phage with each phage containing a 
different DNA fragment. E. coli is spread on an agar plate and infected E. coli create a 
plaque on the bacterial lawn. One phage infects one bacterium so each plaque represents 
a unique DNA sequence. 
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fragments that can be removed and substituted for equally large pieces of genomic DNA. 
Excess lambda arms are added to restriction endonuclease-digested genomic DNA. The 
sticky ends of the DNA fragments hybridize with the lambda arms and are subsequently 
ligated together with DNA ligase. Finally, the DNA is packaged into lambda capsids, 
resulting in lambda phages with random DNA inserts. The product is a library of many 
thousands of recombinant lambda phage each containing a unique fragment of 
chromosomal DNA. 
Preliminary work used genomic DNA from A. actinomycetemcomitans strain 
HK1651 (American Type Culture Collection) and a modified ATriplEx2 vector 
(Clontech) that allows use of the EcoR1 site for making the library. HK1651 is serotype 
b, based on its immune responses to surface antigens. Serotype b is the most prevalent A. 
actinomycetemcomitans serotype in both aggressive and chronic periodontitis (Yang, 
2004). 
ATriplEx2 was initially used because it expresses in all three reading frames, 
decreasing the number of screens necessary to immunoscreen the entire A. 
actinomycetemcomitans genome. However, it did not appear to have the expression levels 
necessary to provide a strong positive signal and clearly differentiate positive from 
negative plaques. As such, all later work (and all results) used Lambda ZAP II 
Expression Library and Gigapack Gold III packaging kit purchased from Stratagene 
(USA). Further, A. actinomycetemcomitans strain lP2 cultures were received from the 
laboratory of Dr. Don Demuth (University of Louisville) and used instead of HK 1651 
genomic DNA. lP2, like HK 1651, is a well characterized serotype b strain. 
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Partial Digestion of Genomic DNA 
To give overlapping fragments, A. actinomyctemcomitans genomic DNA (5 Ilg) 
was partially digested with 5 Units of TSP5091 restriction endonuclease (New England 
Biolabs) for approximately 60 min. Tsp5091 is not sensitive to methylation and cuts at 
the 4-base recognition sequence AATT leaving a 4 base 5'-overhang identical to the 
EcoR 1 overhang on the vector. Since Tsp5091 cuts at a 4-nucleotide target, it is predicted 
to cut random sequence DNA with a frequency of once every 256 bases. 
Digestion was assessed by running an aliquot of digested DNA on 1 % agarose gel 
to verify generation of random length DNA fragments. Fragments from 400-1500 bp in 
size were excised from the gel. The DNA was purified from the gel plugs using Qiagen 
gel purification columns (Qiagen, USA). 
Library Creation Using Lambda Bacteriophage Vector 
Lambda Zap II arms (Stratagene, cat#236612), commercially EcoRI digested and 
Calf Intestinal Alkaline Phosphatase treated, were added to the partially digested 
A.actinomyctemcomitans DNA fragments inserts at a ratio of 1: 1 (500 ng arms to 500 ng 
of DNA) to 3: 1. T4 DNA Ligase (New England Biolabs) was used, in a reaction volume 
of 6 [lL, for an 18 hour incubation at 16°C to ligate lambda arms with the insert to form a 
recombinant lambda phage-genomic DNA strand (Figure 2). The recombinant arms were 
then packaged (ie. addition of phage protein coat) using a lambda packaging reaction, 
Gigapack III Gold Packaging Reaction (Stratagene, cat#200206) for 2 hours at room 
temperature. This phage packaging kit is capable of producing lx108 PFU/llg DNA. 
Recombination efficiency was determined by measuring the loss of B-galactosidase 
acti vity in recombinant phages. The host bacteria, XL 1-Blue MRF', was infected with the 
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packaging reaction and plated in the presence of IPTG and X-gal. Since phage that are 
packaged in vitro are not very stable, half the library was immediately amplified and 
stored at -80°C. 
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Figure 2. Lambda Zap II Cloning Procedure 
1. Construct DNA Library 
2. Isolate Positive Clone 
3. Excise pBluescript Plasmid 
Containing Cloned DNA Insert by 
Co-Infection with Helper Phage 
T1 
~ 
t 
T3 limp' pBlut liptn 
2 1 bp) 
S 
Oil 
Figure 2. Lambda ZapII Cloning Procedure. Lambda ZAP vectors simplify the 
construction of high-titer cDNA libraries and the characterization of inserted DNA. They 
allow easy excision and recircularization of cloned insert DNA from lambda phage and 
eliminate the need for subcloning procedures. 
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Library Characterization 
Libraries were characterized in order to assure a high representation of the 
bacterial genome. Genomic DNA insert sizes were determined by restriction digests of 
cloned inserts. The Lambda ZAP vector allows in vivo excision and recircularization of 
cloned inserts to form a plasmid (phagemid) containing the cloned insert. Signals for 
packaging the phagemid are contained within the f1 terminator origin DNA sequence and 
permit the circularized DNA to be packaged and secreted from the E. coli. Once secreted, 
the E. coli cells used for excision of the cloned DNA can be removed from the 
supernatant by heat treatment. Once the packaged pBluescript DNA is mixed with fresh 
E. coli cells and re-plated, DNA from minipreps of these colonies can be used for 
analysis of insert DNA. 
Details of this method are as follows: Plaques are cored from the agar plate and 
transferred to a sterile microcentrifuge tube containing 500 III of SM buffer and 20 III of 
chloroform. The microcentrifuge tube is vortexed to release the phage particles into the 
SM buffer and incubated overnight at 4°C. Separately, 50 ml of XLI-Blue MRF' cells in 
LB broth with supplements is cultured overnight at 30°C. The next day the cells are 
centrifuged at 1000 x g and resuspended in MgS04. 200 III of cells at an OD600 of 1.0 
are combined with 1 III of the R408 helper phage and the phage from the plaque and 
incubated at 37°C for 15 minutes to allow the phage to attach to the cells. 3 ml of LB 
broth with supplements is added and incubated at 37°C overnight. Next, the tube is 
incubated at 65-70°C for 20 minutes to lyse the lambda phage particles and the cells and 
centrifuged at 1000 x g for 15 minutes to pellet the cell debris. The supernatant 
containing the excised pBluescript phagemid packaged as filamentous phage particles is 
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decanted into a sterile 14 ml round-bottom tube. 200 III of freshly grown XLI-Blue 
MRF' cells are placed in two microcentrifuge tubes and 100 III of the phage supernatant 
is added to one of the tubes and 10 III to the other microcentrifuge tube. The tubes are 
incubated at 37°C for 15 minutes and plated on LB-ampicillin agar plates and incubate 
overnight at 37°C. Colonies contain the pBluescript double-stranded phagemid with the 
cloned DNA insert. 
After isolating the excised plasmid DNA by miniprep (Qiagen), insert sizes and 
numbers were determined by restriction analysis. Acceptable libraries had an average 
insert size greater than 750 bp (3 times the average frequency of Tsp5091 sites), ensuring 
overlapping fragments. The complexity of the library was calculated as the number of 
plaques with inserts per llg of insert DNA (Ausubel, 2000). Phage infected bacteria were 
plated at a density of about 4000 plaques per plate. Screening 50,436 plaques was 
calculated to provide a 95% probability that every section of the genome is represented in 
an expression clone, based on the size of the bacterial genome (2.1 Mb A. 
actinomycetemcomitans ), the average size of the inserts, and the fraction of clones in the 
correct orientation and reading frame (Sambrook, 1989). The probability of having any 
given genomic DNA sequence in the A. actin library can be calculated from the equation 
N In(l-P) 
In(l-f) 
where P is the desired probability, f is the fractional proportion of the genome in a single 
recombination, and N is the necessary number of recombinants. To achieve a 95% 
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probability of having a given DNA sequence represented in a library of 750 bp fragments 
of the 2.1 Mb A. actinomycetemcomitans genome N = InO.05/ln(1-75012.1 Mb) = 8,406 
plaques. N is then multiplied by 3 to correct for reading frame and by 2 for orientation. 
Thus, 8,406 plaques x 6 = 50,436 plaques are necessary to screen in order to have a 95% 
probability of having any given DNA sequence in the library. 
To characterize later libraries, PCR was conducted directly on phage particles to 
determine the frequency and size of inserts. Clear plaques lacking B-gal activity were 
picked and amplified using Amplifier forward and Amplifier reverse primers that span 
the EcoRI insert site and yield a band of 160 bp when no insert is present. PCR products 
were run on a 1.0% agarose gel, for size determination. Gel slices were purified using the 
Qiagen PCR clean-up kit (Qiagen, US) and the PCR products were collected for further 
analysis. 
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Figure 3. peR Analysis of Inserts 
600 bp 
160 bp 
600 bp 
Figure 3. peR Analysis of Inserts. peR Analysis of Inserts. peR was conducted on 
inserts using M13 primers for Lambda Zap II. Bands cut from digest were between 400 
bp and 1500 bp. No inserts would give a fragment of approximately 160 bp. 2 out of the 
10 fragments had no inserts (Lanes 1,5). 80% of fragments contained inserts of the 
anticipated size range based on the partial digest of A. actinomycetemcomitans genomic 
DNA. 
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Immunoscreening Genomic DNA Lambda Phage Expression Libraries 
Analyzing Serum Pools by Western Blotting 
Eleven human serum samples (Innovative Research, Southfield, MI) were pre-
screened to identify highly immunogenic serum by western blotting of bacterial proteins. 
A western blot is an analytical technique used to detect specific proteins in a given 
sample. It uses gel electrophoresis to separate proteins that are then transferred to a 
membrane. Membranes are subsequently probed using antibodies specific to the target 
protein. 
For the western blot analysis of individual serum antibody responses to oral 
bacteria, liquid cultures of A. actinomycetemcomitans, P. gingivalis and E. coli strain 
XLl- Blue were centrifuged to pellet bacteria. The resulting pellets were washed and 
suspended in 100 !!L of LB. The suspensions were then boiled for 15 min at 98°C to lyse 
the bacteria. Lysates were quantified using a Nanodrop (Nanodrop Technologies, USA) 
by absorbance at 280 nm wavelength. The bacterial proteins were separated on a 20% 
polyacrylamide gel (NuSEP, USA) by gel electrophoresis and transferred to a PVDF 
membrane. After blocking with a 5% milk-TBST blocking solution (25 mM Tris, 140 
mM NaC!, 3 mM KCI, 1.0% Tween-20, pH 8.0), the membranes were cut into strips with 
each of the three bacteriallysates on each strip. Strips were then probed overnight at 4°C 
with a 1 :500 dilution of human serum, purchased commercially from Innovative 
Research, Inc. (Southfield, MI) and blocking buffer. Strips were subsequently washed 
liberally with TBST and incubated for 1 hour at room temperature with goat anti-human 
total Ig horseradish peroxidase (HRP) conjugated secondary antibody (Southern Biotech, 
USA) at a dilution of 1 :5000 in blocking buffer. Bound antibodies were visualized by the 
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addition of DAB/CN (Pierce, USA). Chloronaphthol (CN) and diaminobenzidine (DAB) 
are chromogenic peroxidase substrate compounds combined in a single, stable, lOX stock 
solution. The CNIDAB solution produces an intense dark black precipitate at sites of 
bound HRP-conjugated antibodies on probed blots. This identified sera exhibiting a high 
titer of anti- A. actinomyctemcomitans antibodies. Three sera were combined for 
screening the genomic expression library. 
Immunoscreening A. actinomycetemcomitans Genomic DNA Libraries 
Once a library has been constructed, a robust assay is needed to detect and isolate 
the few clones containing antigens out of the millions of clones in the library. 
Identification of a novel antigen involves the following steps: titering the library to 
determine the PFU/ml (plaque forming units per ml of library stock), primary plating of 
the library, preparing filters of phage plaques, screening of filters with human serum, 
secondary screening, tertiary screening, preparation of DNA, and subcloning plus 
sequencing of A. actinomycetemcomitans inserts. 
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Figure 4. Immunoscreening Technique 
Plate with library 
Grow colonies or plaques 
Some clones will contain 
antigenic proteins 
Wash and block membrane 
Add pooled serum 
Add secondary Ab and detect 
Put membrane on plate 
Mark orientation of membrane on plate 
Remove membrane from plate 
Transfer agar to tube 
Figure 4. Immunoscreening Technique. A. actinomycetemcomitans genomic DNA library 
is incubated with the growth culture of excess E. coli bacteria and plated to yield 
approximately 2000-4000 plaques. The plaques appear on a lawn of bacteria whereby 
each plaque represents a unique genomic DNA sequence of A. actinomycetemcomitans. 
A nitrocellulose filter is placed onto the agar plate and by capillary action the plaques are 
replicated on the nitrocellulose. A. actinomycetemcomitans antigens of interest are then 
detected using an immune detection protocol. 
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Once titered, an appropriate amount of the bacteriophage lambda library is 
incubated with the growth culture of excess E. coli bacteria. The bacteriophage infect the 
E. coli and the cells are subsequently spread on agar plates. Plaques which contain the 
debris from the lysed bacteria including the highly expressed A. actinomycetemcomitans 
peptide (antigen), appear on the lawn of bacteria whereby one phage creates one plaque, 
and each plaque represents a unique genomic DNA sequence of A. 
actinomycetemcomitans. For immunoscreening, a library of 2000 to 4000 plaque-forming 
units (PFU) was plated on each petri dish. For each screening, 10-15 petri dishes were 
grown to give approximately 24,000 plaques total. 
As the plaques grow, the lambda bacteriophage lyse the adjacent infected cells. 
Each plaque expresses a high concentration of the peptide cloned into that phage. A 
nitrocellulose filter is placed onto the agar plate and by capillary action the plaques are 
replicated on the nitrocellulose. 
An immune detection protocol is then used to detect the antigens of interest. 
Antigens in different plaques immobilized on nitrocellulose membranes are detected with 
human antibodies in a three-step process. Nitrocellulose membranes are placed into 
individual petri dishes and diluted serum from three pooled patient samples is added to 
each dish. Antibodies in the human serum are termed primary antibodies, and will bind to 
those antigens on the membranes that the antibodies recognize. Since serum presumably 
contains many different antibodies, it is likely that on an individual plate containing 
approximately 2000 unique clones of A. actinomycetemcomitans antigens, that several 
different antibodies will recognize different clones. This means that there will likely be 
one or two antibody/antigen reactions on each membrane. 
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In a second step, a secondary antibody-horseradish peroxidase (HRP) conjugate, 
which recognizes general features of all human antibodies, is added to find locations 
where the primary antibody is bound. In the third step, HRP, the enzyme conjugated to 
the secondary antibody, catalyzes a colorimetric reaction when the appropriate substrate 
is added, resulting in the deposition of colored product on the membrane at the individual 
immunoreactive plaque. This color provides a visual indication of potential primary 
antibody recognition. Positive, reactive plaques are identified, picked from the agar 
plates, and preserved. 
Because of the density of the plates, the wet surface of the plates, and the 
difficulty in picking individual plaques, preserved plaques may contain some 
contaminating phage. To decrease the likelihood of contamination and to confirm that a 
positive plaque was picked, a secondary and tertiary screening is performed. In particular, 
the tertiary screening is conducted at a low enough plaque density to ensure that the final 
preserved plaque isolate is homogenous in nature. 
Once screenings have been completed, each preserved, lambda phage containing 
tertiary plaque is converted into a plasmid. By sub cloning the A. actinomyctemcomitans 
insert from the lambda phage containing plaque into a plasmid vector, the positive A. 
actinomyctemcomitans gene sequence is preserved and is more easily manipulated for 
future studies. 
Details of the above screening process are as follows: Phage infected bacteria 
were plated at a density of 2000 to 4000 plaques per plate. IPTG soaked nitrocellulose 
membranes were placed on each plate and the plates were incubated for 14 hours at 37°C. 
Membranes were removed and washed in TBST-5% milk for 2 hours. 
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Membranes were probed overnight with pooled human sera diluted 1 :500 in 5% 
milk in TBST. Goat anti-human total Ig human horse radish peroxidase (HRP) 
conjugated secondary antibody (Southern Biotech, USA) were used to identify human 
serum Ig bound plaques. Secondary antibodies were incubated with the membranes for 1 
hour. To visualize reactive plaques, chloronapthol (CN) or DABICN (Pierce, USA) was 
added to form a colored precipitate reaction. Plaques corresponding to the colored 
reactive spots on the membranes were picked using disposable glass Pasteur pipettes. 
Recombinant clones were purified through repeated plating, serum screenings, and 
picking of reactive plaques. 
Identifying and Characterizing A. actinomyctemcomitans Antigens 
Each plasmid generated from identified immuno-positive tertiary plaques was 
sequenced to identify the proteins expressed. Purified phage clones were amplified and 
the pBluescript plasmid with the insert was excised following manufacturer's protocols. 
Plasmid clones were sequenced at the University of Louisville Nucleic Acids Core 
facility. pBluescript forward and reverse sequencing primers were provided to the Core 
facility for sequencing and to confirm correct insert orientation. 
Sequence Identification 
A. actinomycetemcomitans clone sequences were compared to the published 
genome using the Basic Local Alignment Search Tool (BLAST) on the lCVI website 
(cmr.jcvi.org), on the ORALGEN website (www.oralgen.lanl.gov) or the NIH website 
(blast.ncbi.nlm.nih.gov). The sequences of the insert DNA and 7 codons upstream of the 
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EcoRI insert site were compared to the databases to identify A. actinomycetemcomitans 
genes encoded within the insert. DNA inserts disrupt the coding sequence for ~­
galactosidase since they are inserted within that sequence. Peptides are expressed as a 
fusion protein with the first 7 amino acids of ~-galactosidase. This ensures the presence 
of an initiator methionine. However, it also means that only one reading frame can be 
expressed. The BLASTx option was utilized to ensure that the insert was in the correct 
reading frame. Since a group of three nucleotides code for a single peptide, a totally 
different polypeptide can be transcribed depending on whether reading starts with the 
first, second, or third nucleotide. BLASTx (Basic Local Alignment Search Tool) is used 
to compare a newly determined DNA sequence against already existing sequences in the 
NCBI non redundant protein database. 
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RESULTS 
Genomic DNA Lambda Expression Library Creation 
The steps in the creation of the A. actinomycetemcomitans Genomic DNA 
Lambda Expression Library are as follows: 
1. Partial Digestion of A. actinomycetemcomitans genomic DNA 
2. Ligation and packaging of the Genomic DNA Lambda Expression Library 
3. Characterization of the A. actinomycetemcomitans Expression Libraries 
Partial Digestion of A. actinomycetemcomitans Genomic DNA 
A. actinomyctemcomitans genomic DNA (0.4 Ilg) was partially digested with 
varied amounts of TSP5091 restriction endonuclease to identify the optimal ratio of 
enzyme to DNA. Digestion was assessed by running an aliquot of digested DNA on 1 % 
agarose gel to verify generation of random length DNA fragments. Based on the results 
in Figure 5, the ideal ratio of TSP5091 to A. actinomyctemcomitans DNA was 3.3 
Units/ug DNA. Subsequently, a preparative digestion was done using 16.5 U TSP5091 
and 5 Ilg genomic DNA. The entire reaction was fractionated on an agarose gel. 
Fragments from 400-4000 bp in size were excised from the gel. The gel plugs were 
purified using Qiagen gel purification columns (Qiagen, USA). The pooled DNA was 
used for library construction. 
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Figure 5. Analytical and Preparative Partial Digests of A.a. Genomic DNA 
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Figure 5. Analytical and Preparative Partial Digests of A. actinomycetemcomitans 
Genomic DNA. A. For analysis, A. actinomyctemcomitans genomic DNA (0.4 Jlg) was 
partially digested with TSP5091 restriction endonuclease. Tube 1 contains 4 Units of 
TSP5091. Tubes 2-5 were serial dilutions as follows: 1.33 U, .44 U, .15 U, .07 U). 
Conditions were optimized by running the partial digestions on 1 % agarose gels. Based 
on the results, the ideal ratio of TSP5091 to A. actinomyctemcomitans genomic DNA was 
3.3 U/ug DNA (Lane 2). B. For library construction, 5 ug of A. actinomyctemcomitans 
genomic DNA was partially digested with 16.5 Units of TSP5091 restriction 
endonuclease. Fragments from 400-1500 bp in size were excised from the gel, and 
purified using Qiagen gel purification columns (Qiagen, USA). 
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Ligation and Packaging of Genomic DNA A Expression Library 
Commercially available Lambda Zap II arms (Stratagene) were added to the 
partially digested A.actinomyctemcomitans DNA fragment with T4 DNA Ligase (New 
England Biolabs) and incubated overnight to ligate lambda arms to the insert. The 
overhang left by the TSP5091 digestion matches and ligates with the EcoR 1 overhangs 
on the ends of the lambda arms. The resultant recombinant lambda phage-genomic DNA 
strands were then packaged by the addition of phage coat proteins using a lambda 
packaging reaction, Gigapack III Gold Packaging Reaction (Stratagene). 
Characterization of the A. actinomycetemcomitans Expression Libraries 
Recombination efficiency was determined by measuring the loss of ~­
galactosidase activity in recombinant phages. Lambda arms which ligate to each other 
without a DNA insert encode the beta-galactosidase enzyme across the ligation site. The 
presence of an insert disrupts the galactosidase sequence. The host bacteria, XLI-Blue 
MRF', was infected with the packaging reaction and plated in the presence of IPTG and 
~-galactosidase. Lambda Zap II:A. actinomycetemcomitans expression libraries were 
found to have relatively high titers of approximately Ix107 PFU/ug DNA. Less than 10% 
of the plaques showed beta-galactosidase activity, demonstrating a recombination 
efficiency of >90%. 
We next investigated whether the insert sizes in the phage library matched the 
expected size range. PCR amplification of random recombinant clones was done using 
M13forward and M13reverse primers and published PCR protocols. Results in Figure 6 
show bands were diverse sizes between 200-1400 bp consistent with random fragments. 
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Further, to confirm diverse portions of the A. actinomycetemcomitans genome were 
cloned, Ten inserts were sequenced and aligned to the A. actinomyctemcomitans genome. 
Inserts appeared to be randomly selected from different areas of the bacterial 
chromosome. Since phage that are packaged in vitro are not very stable, half the library 
was immediately amplified and stored. 
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Figure 6. Size Determination of Expression Library Inserts 
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600 bp 
Figure 6. Size Determination of Expression Library Inserts. Phage particles from "white" 
(~-gal activity negative) plaques were directly peR amplified using Amplifier Forward 
and Reverse primers that encompass the EcoR1 insert site. Negative inserts yield a 160 
bp band. Bands range in size from 200-1400 bp. 
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Immunoscreening Genomic DNA Lambda Phage Expression Libraries 
Western Blot Analysis of Individual Serum Antibody Responses to Bacteria 
Western blot analysis of bacteriallysates was used to determine the relative 
antibody titer in each human serum sample. This step ensures that the original serum 
samples were immunoreactive to a broad range of A. actinomycetemcomitans antigens 
and had sufficient antibody titers for immunoscreening. Bacteriallysates for E.coli, P. 
gingivalis, or A. actinomycetemcomitans were run on SDS-PAGE gels and transferred to 
PVDF membranes. Membranes were probed overnight with individual serum aliquots 
(1 :500 dilution) followed by goat a-human Ig secondary antibody. CNIDAB substrate 
was added for visualization of results. Antibody titers in some sera (e.g. serum samples 
#3 and #4) were found to be too low for use in screening of A. actinomycetemcomitans 
libraries. Instead, high titer sera (e.g. serum samples #1, #2, and #8) were chosen to be 
used for screening of the expression libraries. 
The antigenic bands identified differed between bacterial species. A. 
actinomycetemcomitans often had more antigenic bands and more intense staining than P. 
gingivaiis, but not always. Serum from different individuals recognized different 
antigenic proteins in A. actinomycetemcomitans extracts, with different intensities. Thus, 
the high variability in individual serum antibody response must be taken into 
consideration when choosing sera for screening of expression libraries. This is 
un surprising considering it strongly supports the project's approach which is based on the 
idea that individuals have different profiles of antibodies. 
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Figure 7. Western Blot Analysis: Individual Serum Antibody Responses to Bacteria 
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Fiqure 7. Western blot analysis of individual serum antibody responses to oral bacteria. 
Iflg of total bacterial lysate for E.coli (E), P. gingivalis (P), or A. actinomycetemcomitans 
(A) was run on a SDS-PAGE gel and transferred to PVDF membrane. Membranes were 
probed overnight with serum from different individuals using aliquots at 1:500 dilution. 
Goat a-human total Ig at 1: 10k dilution secondary antibody was used and CNIDAB 
substrate was added for visualization of results. Responses to A. actinomycetemcomitans 
are variable between patients with regard to banding patterns and antibody titers. 
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Immunoscreening A. actinomycetemcomitans Genomic DNA Libraries 
Membranes from ZAPII: A. actinomycetemcomitans plates were incubated with 
serum pools, 1 :500 in blocking buffer, overnight before incubation for 1 hour with 
secondary antibody goat a-human total Ig (HRP conjugated) followed by CN:DAB for 
visualization. In Figure 8A, an individual immunoreactive plaque (box) is seen among 
approximately 200 plaques in panel field. Plugs from immunoreactive plaques were 
picked and re-screened for clone isolation. Secondary plating, Figure 8B, increased the 
percentage of positive clones while tertiary plating (Figure 8C) allowed for isolation of 
pure clones. As can be seen in Figure 8, each successive plating increased the percentage 
of positive clones. Each blot also included a positive control spot of crude A. 
actinomycetemcomitans lysate. 
About 100,000 plaques have been screened and 72 immunoreactive clones have 
been isolated. Of the 72 immunoreactive clones picked, 26 made it through primary, 
secondary, and tertiary screening. 
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Figure 8. Serum Screening for Immunoreactive Plaques and Clone Isolation 
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Figure 8. Serum Screening for Immuno-reactive Plaques and Clone Isolation. Membranes 
from Lambda ZAPII: A. actinomycetemcomitans plates were incubated with serum 
pools, 1 :500 in blocking buffer (5% milk in TBST), overnight before incubation for 1 
hour with HRP conjugated secondary antibody goat a-human total Ig at 1: 10,000. In 
panel A, an individual immunoreactive plaque (box) is seen among -200 plaques in panel 
field. Immunoreactive plaques were picked and re-screened for clone isolation. 
Secondary screening (panel B) of the plaque from panel A exhibits an increased ratio of 
reactive plaques (dark spots) to non-reactive plaques (light spots) . Panel C shows that all 
the plaques in this tertiary screen are positive. 
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Identifying Positive A. actinomyctemcomitans Gene Sequences 
Each plasmid generated from identified immunopositive tertiary plaques was 
sequenced to identify the proteins expressed. This study used the Nucleic Acids Core at 
the University of Louisville for sequencing. A. actinomycetemcomitans clone sequences 
were compared to the published genome using BLAST on the ICVI website 
(cmr.jcvi.org), on the ORALGEN website (www.oralgen.lanl.gov), or on the NIH 
website (blast.ncbi.nlm.nih.gov). Figure 9 shows a typical BLAST analysis of the DNA 
sequence of an antigenic peptide found through tertiary screening of clones. Analyses 
compare the nucleotide sequence of the clone with that found in the database and provide 
a detailed description of proteins with significant homology. 
From the sequences, the insert DNA and 7 codons upstream of the EcoRI insert 
site were blasted using the TIGR-CMR BLAST database to identify A. 
actinomycetemcomitans genes encoded within the insert. The BLASTx option was 
utilized to insure that the insert was in the correct reading frame. All sequenced tertiary 
screened clones were in the correct reading frame. The genes identified are listed in Table 
1. Table 2 includes more detailed information about the A. actinomycetemcomitans genes. 
Column 1 of Table 2 gives the Los Alamos National Laboratories gene number. Column 
2 gives the gene name. Columns 3,4, and 5 give the nucleotide identity, gaps in the 
sequence identification and E value, respectively. Columns 5, 6, and 7 give the protein 
definition, gene length and the functional class of the protein. 
Of these, 7 antigenic peptide sequences appeared to be similar to others we had 
identified, while the remaining 19 antigenic peptide sequences appeared unique. Of the 
19 unique antigens identified, eight appear to be proteins displayed on the bacterial cell 
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wall, while the remaining eight appear to be protoplasmic proteins. 17 of the 19 unique 
antigens have not been studied in A. actinomycetemcomitans and were instead found 
through homology to proteins in other species. 
The identity of the 19 unique antigens was determined by a comparative analysis 
of their nucleotide sequences. The comparative analysis showed an 84% or greater 
homology between the sequence of clones and the sequence in the database. 18 of the 19 
unique antigens showed a homology of 93% or greater. Genes ranged in length from 279 
bp to 3168 bp. 
36 
Figure 9. Blast Search of A. actinomycetemcomitans Clone Sequence 
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Figure 9. Blast Search of A. actinomycetemcomitans Clone Sequence. This is an example 
of a BLAST analysis of an antigen found through tertiary screening of clones. The 
BLAST results show that the antigenic protein is most likely a conserved hypothetical 
protein that has not been studied in A. actinomycetemcornitans. 686 bp out of 687 bp 
were identical to the database' s sequence of the conserved hypothetical protein. All 
tertiary screened clones had a homology with the database of greater than or equal to 
84%. 
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Table 1. Antigenic Genes of Aggregatibacter actinomycetemcomitans Identified 
Through the Use of Whole Genome Protein Expression Libraries 
Novel* 
hgpA Hemoglobin binding protein A No 
hgpAb Hemoglobin binding protein A No 
fecS Iron (III) dicitrate-binding periplasmic Yes 
ftsA Cell division protein A Yes 
I peA Phosphoheptose isomerase Yes 
acrB Acriflavine resistance protein Yes 
atpA ATP synthase Fl, subunit alpha Yes 
mutL DNA mismatcvh repair protein Yes 
amiS N-acetylmurmoyl-L-alanine amidase II Yes 
dsbA Thiol-disulfide interchange protein Yes 
cbiQ Cobalt membrane transport protein Yes 
rplY 50S ribosomal protein L25 Yes 
hipS Lipoprotein Yes 
pbpG Penicillin-binding protein Yes 
Unknown 1 Hypothetical protein Yes 
pykA Pyruvate kinase II Yes 
Unknown 2 Conserved hypothetical protein Yes 
hypF Hydrogenase maturation protein Yes 
Unknown 3 Conserved hypothetical protein Yes 
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Table 2. A.a. Antigen Table 
Gene 
Number Nucleotide Gene A. Sequences Producing Significant 
LANL Gene Name Identity Gaps E Value Definition Length Functional Class Alignments 0\ ('() 
AA01751 CbiK 686/687 (99%) 1/687 (0%) o Putative peri plasmic binding protein 759 Cobalt chelatase protein putative ABC-type Co2+ transport 
Cell envelope; murein 
sacculus and 
AA02101 pbpG 240/283 (84%) 4/283 (1%) 2.00E-57 Penicillin-binding protein 7 279 peptidoglycan penicillin-binding protein 7 
AA01751 213/217 (98%) 3/217 (1%) 1.00E-l04 Conserved Hypothetical Protein 
AA01751 464/466 (99%) 21466 (0%) o Conserved Hypothetical Protein 
Central intermediary 
AA02682 hypF 690/699 (98%) 4/699( 0%) o Hydrogenase maturation protein 2283 metabolism Hydrogenase maturation protein 
hgpA, hgbA, Transport and binding 
AA00763 hamA 269/278 (96%) 4/278 (1%) 1.00E-126 Hemoglobin binding protein A 1785 proteins ; cations Hemoglobin binding protein 
AAOl341 acrB 370/370 (100%) 0 o Acriflavine resistance protein 3168 Drug sensitivity acriflavine resistance protein 
Cell envelope; murein 
sacculus and 
AA01588 amiB 718/722 (99%) 21722 (0%) o N-acetylmuramoyl-l-alanine amidase II 1485 peptidoglycan N-acetylmuramoyl-l-alanine amidase II 
AA02099 rplY 170/ 178 (95%) 7/178 (3%) 4.ooE-62 50S ribosomal protein L25 285 Translation rpl25 
AA01756 cbiQ 400/401 (99%) 1/401 (0%) o cobalt membrane transport protein 672 
AA00830 ftsA 218/221 (98%) 3/221 (1 %) 1.00E-l09 cell division protein A 1278 cell division cell division protein ftsA 
AA01586 mutl 469/474 (98%) 4/474 (0%) o DNA mismatch repair protein 1848 DNA repair Mutl 
iron (III) dicit rate-binding periplasmic 
AA00795 lecB, leoB 1421147 (96%) 2.ooE-64 protein precursor 
Table 2. continued 
A.a. Antigen Table 
Gene 
Number Gene 
LANL Name 
Nucleotide 
Identity Gaps E Value Definition 
AA00795 fecB, feoB 1421147 (96% ) 
iron (III) dicit rate-binding peri plasmic 
2.00E-64 protein precursor 
hgpA, 
AA00764 hamA 
AA02214 pykA 
IpcA, 
193/198 (97%) 4/198 (2%) 2.00E-88 Hemoglobin binding protein A 
718n35 (97%) 6/745 (0%) O.OOE+OO pyruvate kinase II 
AA00860 gmhA, isn 268/271 (98%) 0 1.00E-146 phosphoheptose isomerase 
AA01751 597/599 (99%) 21599 (0%) O.OOE+OO Conserved Hypothetical Protein 
AA02100 hlpB 
AA02613 
AA01748 dsbA 
hgpA, 
hgbA, 
AA00763 ham A 
hgpA, 
hgbA, 
AA00763 hamA 
hgpA, 
hgbA, 
AA00763 hamA 
AA01486 atpA 
AA02115 
558/596 (93%) 6/596 (1 %) O.OOE+OO lipoprotein 
3921396 (98%) 1/396 (0%) O.OOE+OO Conserved Hypothetical Protein 
248/248 (0%) o 1.00E-139 thiol:disulfide interchange protein 
401/416 (96%) 8/416 (1 %) O.OOE+OO Hemoglobin binding protein A 
553/560 (98%) 4/560 (0%) O.OOE+OO Hemoglobin binding protein A 
4221433 (97%) 4/433 (0%) O.OOE+OO Hemoglobin binding protein A 
617/624 (98%) 6/624 (0%) O.OOE+OO ATP synthase F1, subunit alpha 
Hypothetical protein (Also possible 
AA01289 & AA01075 hypothetical 
378/380 (99%) 0 O.OOE+OO proteins with same (0) E-value) 
Gene 
Length Functional Class 
Transport and binding 
A_ Sequences Producing Significant 
Alignments 
891 proteins, ABC superfamily Beta-D-galactosidase (Iacl) 
Transport and binding 
420 proteins; cations 
Central intermediary 
metabolism (glycolysis & 
gluconeogenesis - Carbon 
1506 fixation) 
Cell enwlope, surface 
582 polysaccharides 
759 Unknown 
TonB-<lependent receptor, putatiw. 
Different LANL Gene Number than 
Tertiary 6 
PykA 
GmhA 
Same as #T1 
663 Cell enwlope; membranes Lipoprotein HlpB 
783 Unknown Unknown 
Translation; Protein 
669 modification 
Transport and binding 
1785 proteins; cations 
1539 Enery metabolism 
384 Unknown 
Thiol:disulfide interchange protein 
A TP synthase alpha chain 
Integrase 
o 
-.:::t 
DISCUSSION 
A novel research technique was developed to discover antigenic proteins from the 
periodontal bacterium, A. actinomycetemcomitans. The technique takes advantage of the 
the high gene density of the bacterial genome (i.e., no introns), the efficiency of 
transformation by lambda vectors, and the high level of protein expression in plaques 
created by lambda phage. After generating A. actinomycetemcomitans genomic DNA 
expression libraries, the libraries were plated and then probed using human serum to 
identify periodontal antigens. Identified antigens then undergo additional screenings to 
confirm and define antigenicity. Bacteriophage encoding antigens were converted to 
plasmids for archiving and sequenced for gene identification. 
The A. actinomycetemcomitans whole genome protein expression libraries were 
made using the Lambda ZapII library construction kit. Libraries consisted of random 
sized inserts correlating to a range of about 400 to 1400 bp in size. The key insight that 
allowed this project to proceed is that complex libraries can be screened from small 
fragments of genomic DNA with an efficiency that will theoretically provide unbiased 
and complete coverage of all bacterial antigens. My results demonstrated that the 
unbiased A.actinomycetemcomitans genomic DNA expression libraries expressed A. 
actinomycetemcomitans proteins at a high level that allowed subsequent screening with 
human serum. 
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Individual patient serum antibody responses to oral bacteria played a large part in 
the detection of bands by Western blotting. Individual serum antibody responses were 
highly variable and had to be taken into consideration when choosing sera for screening 
of expression libraries (Figure 7). Pooling of the most antigenic sera as determined by 
staining intensity and band dispersion provided optimum results and resulted in a greater 
number of positive plaques. 
Immunoscreening of A. actinomycetemcomitans libraries allowed the 
identification of antigenic plaques which were subsequently isolated and sequenced. 
U sing this technique, 26 antigens were identified, 19 of which were unique. 17 of the 19 
novel antigens have not been studied in A. actinomycetemcomitans. 
The new antigens include a variety of functions, being involved with metabolism, 
in the hemoglobin binding family, responsible for drug resistance, or of unknown 
functions. Two of the proteins are recognized as virulence factors, pbpG, a penicillin-
binding protein (Keseler, 2005) and integrase (Chen, 2009), which mediates integration 
of a DNA copy of the microbe genome into the host chromosome. Further, eight of the 
antigens are found extracellularly while eight are only found intracellularly. The presence 
of antibodies to cell wall antigens may indicate the individual has either current or recent 
active infection. The presence of antibodies to cytosolic antigens may indicate that 
bacteria are being effectively destroyed, making cytosolic proteins available to the 
immune response. The variety of different antigenic proteins suggests that a clustal 
analysis of antibodies as biomarkers may be a more productive approach than function-
based analysis. That is, identification of a profile of multiple antibodies present in an 
individual may relate to the future progression of disease. 
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Over the last decade, approximately 23 A. actinomycetemcomitans antigens have 
been published where assignment to the bacterial gene was possible, a necessary step for 
identification of the antigenic protein. The novel antigens reported here have significantly 
increased the number of known A.actinomycetemcomitans antigenic genes. The limited 
overlap between these antigenic clones and the previously reported antigenic genes 
suggests that there are large numbers of uncharacterized antigens. 
The novel immunoscreening technique is effective in identifying periodontal 
antigens. Future studies should use additional human sera to identify any other A. 
actinomycetemcomitans periodontal antigens. The identification of reactive A. 
actinomyctemcomitans bacterial antigens opens new approaches to the diagnosis and 
treatment of periodontal disease. Among the new approaches are vaccine candidates, 
pharmaceutical drug discovery assays, and serodiagnostic assays for research and clinical 
purposes. To attain these goals, additional studies will need to correlate the presence of 
specific antibodies to the progression of periodontal disease. 
Identification of A. actinomyctemcomitans antigens may suggest vaccine 
candidates (Etz, 2002). For example, by identifying the antigens with the strongest 
association with mild disease or that protect from disease, one could develop novel 
vaccine candidates for immunization to prevent periodontal disease in susceptible 
populations (Page, 2000). Such a vaccine could reduce morbidity associated with 
periodontal disease and linked systemic diseases. 
Additionally, the identification of reactive A. actinomyctemcomitans antigens may 
have utility as a diagnostic tool. Currently, characterization of periodontitis is 
predominantly based on clinical findings. However, a laboratory test has the potential to 
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provide a prognostic serodiagnosis predicting the probability of future severe disease or 
the patient's response to treatment. This would direct the clinician's treatment decisions. 
For example, a patient with a high probability of future severe disease may be treated 
more aggressively than one with a low probability of future disease. 
Microarrays could potentially provide such a diagnostic tool. Protein micro arrays 
provide a multiplex approach to detect proteins, monitor their expression levels, and 
investigate protein interactions and functions. Through automation, protein microarrays 
can carry out large numbers of determinations in parallel, achieving efficient and 
sensitive high throughput protein analysis. Determinations can be carried out with 
minimum use of materials while generating large amounts of data. Research with protein 
micro arrays includes protein-antibody, protein-protein, protein-ligand or protein-drug, 
enzyme-substrate screening and multianalyte diagnostic assays. 
Antigen micro arrays are a subset of protein arrays that provide a rapid, high-
throughput approach to serodiagnosis. Antigen array technologies enable large-scale 
profiling of the specificity of antibody responses against autoantigens, tumor antigens and 
microbial antigens. They provide insight into pathogenesis, and will enable development 
of novel tests for diagnosis and guiding therapy in the clinic (Robinson, 2006). Multiple 
putative antigen proteins are spotted on the array, and are probed with patient serum to 
define the patient's specific antibody profile or combinatorial pattern. Bacarese-Hamilton 
(Bacarese-Hamilton, 2004) found strong concordance between antigen microarrays and 
ELISA, the most common technique for serodiagnosis of microbial infections. This 
proof-of-principal for antigen micro array-based serodiagnosis of infectious disease opens 
up new opportunities to identify multiple specific antibodies in a patient's serum. 
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The identification of reactive A. actinomyctemcomitans bacterial antigens is a key 
component to developing a serodiagnostic assay for periodontal disease. This thesis 
research is the first step in developing such an assay. Identified antigens could be 
screened by microarray to compare antigen profiles of individual periodontitis patients 
and control subjects. Such profiles may be invaluable in the positive identification of 
antigens which could either confer resistance to periodontitis or contribute to disease. 
In summary, we developed an A. actinomycetemcomitans expression library and 
immunoscreening method in order to identify specific bacterial protein antigens that elicit 
humoral immune responses during periodontal disease infection. Using this technique, 19 
A. actinomycetemcomitans antigens recognized by some humans were identified. These 
novel antigens could have diagnostic utility as well as immunization potential for the 
diagnosis and prevention of periodontal disease. 
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